Microbiota Sequencing
Othervirome, bacteriome, fungome NGS sequencing
NCT Number: NCT03983473
The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Central Hospital, Nancy, Lorraine, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
virome, bacteriome, fungome NGS sequencing
Time frame: + 6 months
Alpha (number of species) and Beta diversity (distribution of species)
Time frame: + 6 months
Alpha (number of species) and Beta diversity (distribution of species)
Time frame: + 6 months
Alpha (number of species) and Beta diversity (distribution of species)
Contact information is provided by the study sponsor or research team.
Central Hospital, Nancy, France
Other
Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease. Identification de Biomarqueurs de SPondylArthrite Chez Les Patients Atteints de Maladie de CROhn présents Dans le MICrobiote fécal.
Acronym: MICROSPA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04191395
Arthritis, Arthritis, Psoriatic
Besançon, France
View Trial DetailsNCT06206811
Arthritis, Blau Syndrome
Melbourne, Victoria, Australia
View Trial DetailsNCT04798625
Arthritis, Arthritis, Psoriatic
Lørenskog, Norway
View Trial DetailsNCT03359642
Arthritis, Bone Diseases
Pessac, France
View Trial Details